drugset / Trial / NCT03093545

Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vaccination in Obese Patients

NCT03093545

Non-randomizedParallel-groupOpen-labelTreatment

Summary

A single center, prospective cohort, open-label study of rabies post exposure program with equine rabies immunoglobulin (ERIG) and purified chick-embryo cell (PCEC) rabies vaccine in WHO category III exposed patients at Siriraj Hospital, Thailand aims to compare serum RVNA responses between obese (BMI \> 30 kg/m2) and normal weight/underweight (BMI \< 25 kg/m2) and to evaluate adverse events occurring after immunization on days 7, 14 and 28.

Timeline

Start
2015-03
Primary completion
2016-10
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Equine Rabies Immunoglobulin Protein / enzyme biologic 40 iu/kg
Subject Purified chick-embryo cell rabies vaccine Vaccine 1 ml

Indications